Wells Fargo
BBIO icon

Wells Fargo’s BridgeBio Pharma BBIO Stock Holding History

Wells Fargo’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.57M Sell
88,205
-44,335
-33% -$3.11M ﹤0.01% 2584
2026
Q1 		$9.84M Sell
132,540
-99,722
-43% -$7.23M ﹤0.01% 2042
2025
Q4 		$17.8M Buy
232,262
+83,141
+56% +$5.46M ﹤0.01% 1573
2025
Q3 		$7.75M Sell
149,121
-278,368
-65% -$13.6M ﹤0.01% 2214
2025
Q2 		$18.5M Buy
427,489
+326,054
+321% +$11.9M ﹤0.01% 1464
2025
Q1 		$3.51M Buy
101,435
+13,435
+15% +$453K ﹤0.01% 2694
2024
Q4 		$2.41M Buy
88,000
+18,322
+26% +$473K ﹤0.01% 3057
2024
Q3 		$1.77M Sell
69,678
-2,030
-3% -$53.3K ﹤0.01% 3132
2024
Q2 		$1.82M Buy
71,708
+16,411
+30% +$449K ﹤0.01% 3054
2024
Q1 		$1.71M Buy
55,297
+8,686
+19% +$295K ﹤0.01% 3100
2023
Q4 		$1.88M Sell
46,611
-36,312
-44% -$1.09M ﹤0.01% 2958
2023
Q3 		$2.19M Sell
82,923
-53,242
-39% -$1.51M ﹤0.01% 2739
2023
Q2 		$2.34M Buy
136,165
+70,300
+107% +$1.06M ﹤0.01% 2764
2023
Q1 		$1.09M Buy
65,865
+64,494
+4,704% +$752K ﹤0.01% 3311
2022
Q4 		$10.4K Sell
1,371
-4,961
-78% -$47.5K ﹤0.01% 5536
2022
Q3 		$62K Sell
6,332
-2,249
-26% -$23.4K ﹤0.01% 4844
2022
Q2 		$77K Sell
8,581
-26,737
-76% -$224K ﹤0.01% 4795
2022
Q1 		$359K Sell
35,318
-39,431
-53% -$405K ﹤0.01% 4637
2021
Q4 		$1.25M Buy
74,749
+6,553
+10% +$277K ﹤0.01% 3934
2021
Q3 		$3.2M Buy
68,196
+31,585
+86% +$1.69M ﹤0.01% 3258
2021
Q2 		$2.23M Sell
36,611
-52,179
-59% -$2.98M ﹤0.01% 3587
2021
Q1 		$5.47M Buy
88,790
+16,255
+22% +$1.06M ﹤0.01% 2758
2020
Q4 		$5.16M Buy
72,535
+31,879
+78% +$1.54M ﹤0.01% 2722
2020
Q3 		$1.52M Sell
40,656
-6,718
-14% -$211K ﹤0.01% 3531
2020
Q2 		$1.54M Buy
47,374
+8,953
+23% +$273K ﹤0.01% 3466
2020
Q1 		$1.11M Buy
38,421
+24,431
+175% +$757K ﹤0.01% 3479
2019
Q4 		$490K Buy
13,990
+844
+6% +$23.4K ﹤0.01% 4388
2019
Q3 		$282K Buy
+13,146
New +$364K ﹤0.01% 4753

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Wells Fargo's BBIO Position: Q2 2026 in Review

Wells Fargo reduced its BridgeBio Pharma (BBIO) stake by 33% in Q2 2026, selling an estimated $3.11M and leaving 88,205 shares worth $6.57M. The position accounts for ﹤0.01% of the portfolio, ranked #2584.

Wells Fargo first reported a position in BBIO in Q3 2019 and has held it in 28 quarters since. The position peaked at $18.5M in Q2 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Wells Fargo held 88,205 shares of BridgeBio Pharma worth $6.57M as of Q2 2026.
  • Wells Fargo sold 44,335 BridgeBio Pharma shares in Q2 2026, an estimated $3.11M.
  • BridgeBio Pharma made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #2584 holding.
  • Wells Fargo first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 28 quarters since.
  • Wells Fargo's BridgeBio Pharma position peaked at $18.5M in Q2 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.